Lantheus's exit filing removes a major strategic holder and potential acquirer from the stock. The sales at declining prices ($2.75 then $0.80) suggest diminishing conviction. Monitor for any new strategic investor or further insider selling; the stock now lacks a large supportive shareholder.
CATX drugs
CATX drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $0.9431entry
- T+1 · 18h ago −2.05%α −0.13% · $0.9238
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Lantheus Holdings (via its subsidiary Lantheus Alpha Therapy) filed Amendment No. 4 to its Schedule 13D, reporting a reduction in its stake in Perspective Therapeutics from above 5% to 3.9% (4,739,011 shares). The filing discloses open-market sales of 1,000,000 shares on October 5, 2026 at $2.75/share and 3,000,000 shares on November 10, 2026 at $0.80/share. The Reporting Persons state this is the final amendment and an exit filing, signaling they have ceased to be a 5% beneficial owner and are no longer actively engaged as an activist holder.
Key Financial Metrics
Key Facts
- Lantheus Alpha Therapy sold 1,000,000 shares on Oct 5, 2026 at avg $2.75/share and 3,000,000 shares on Nov 10, 2026 at avg $0.80/share.
- Beneficial ownership reduced to 4,739,011 shares (3.9% of 120,758,815 shares outstanding as of Nov 4, 2026).
- Filing is designated as the final amendment and exit filing; Lantheus no longer a 5% holder.
- Sales occurred just after Q3 2026 earnings (Nov 9, 2026) which reported a wider net loss of $32.4M.
Financial Impact
Lantheus sold 4,000,000 shares total for approximately $5.15M (1M at $2.75 + 3M at $0.80). Remaining stake of 4,739,011 shares valued at roughly $3.8M at the $0.80 sale price.
Risk Factors
- Loss of a significant strategic investor and potential acquirer (Lantheus had a prior investment agreement and collaboration).
- The exit filing may signal Lantheus sees limited near-term upside or has shifted strategic priorities away from CATX.
- Remaining 3.9% stake could be sold in the open market, adding further supply.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13D/A Filing (Primary) | 0001193125-26-458595 |
| Document: 0001193125-26-458595-index.html | 0001193125-26-458595 |
| Document: 0001193125-26-458595.txt | 0001193125-26-458595 |
Track record
34 reports on CATX
2 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +12.27% at T+5 after the Nov 5, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $0.9238 Now $0.9200 −0.41% settles Nov 18
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry $0.9652 Now $0.9200 −4.68% settles Nov 17
- Nov 12, 20264d ago SC 13D/A Bearish 6/10 Viewing Entry $0.9431 to $0.9238 Now $0.9200 +2.45% ▲ +2.05% +0.13% vs SPY
- Nov 10, 20266d ago SC 13G Neutral 2/10 Entry $0.7864 to $0.8252 Now $0.9200 +16.99% ▲ +4.93% +3.62% vs SPY
- Nov 9, 20267d ago 8-K Neutral 4/10 No price data
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $0.7864 to $0.8252 Now $0.9200 +16.99% ▲ +4.93% +3.62% vs SPY
- Nov 6, 202610d ago 8-K Neutral 4/10 Entry $0.8400 to $0.8556 Now $0.9200 +9.52% ▲ +1.86% −0.51% vs SPY
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $0.8400 to $0.8556 Now $0.9200 +9.52% ▲ +1.86% −0.51% vs SPY
- Nov 6, 202610d ago 8-K Neutral 4/10 Entry $0.8400 to $0.8556 Now $0.9200 +9.52% ▲ +1.86% −0.51% vs SPY
- Nov 5, 202611d ago Press Release Bullish 6/10 Entry $0.8400 to $0.8556 Now $0.9200 +9.52% ▲ +1.86% −0.51% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers